Conference Reports for NATAP

Back

The Liver Meeting AASLD 2025 Washington, D.C. November 7-11, 2025 CA   This information is brought to you by NATAP and is not sponsored by, nor a part of, the American Association for the Study of Liver Diseases or The Liver Meeting® or The Liver Meeting Digital Experience ™     Multiscale modeling of results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection - (11/25/25)   No Impact of RASs on the High Efficacy of BEM and RZR in Combination: Resistance Analysis from a Phase 2 Study in HCV-infected Patients - (11/25/25)   Bemnifosbuvir and Ruzasvir Provided as a Fixed-Dose Combination Demonstrates High Relative Bioavailability to Their Individual Formulations and Can Be Dosed With No Regard to Food - (11/25/25)   Impact of Baseline HBeAg Status on HBV Outcomes in the ALLIANCE Study - (11/24/25)   Characterization of HIV/HBV Co-infected Participants Achieving High Rates of Hepatitis B Surface Antigen (HBsAg) Loss in the ALLIANCE Phase 3 Clinical Study - (11/24/25)   Hepatitis C in Pregnancy: Evaluating Screening and Management Practices in a Rural Population - (11/24/25)   Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment-Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184, With or Without Entecavir (ETV) - (11/24/25)   Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small molecule PD-L1 inhibitor, in chronic hepatitis B (CHB) subjects - (11/24/25)   Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro - (11/24/25)   Analysis of Immune Responses in HIV/HBV Co-Infected Participants Experiencing HBsAg Loss After TDF/TAF-Based Antiviral Therapy in the ALLIANCE Clinical Study - (11/24/25)   Metabolic comorbidities and the risk of liver-related events in individuals with hepatitis B virus infection - (11/24/25)   Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results From a Phase 1b Study in Virally Suppressed Patients With Chronic Hepatitis B - (11/24/25)   Retrospective analysis of B-Clear study HBsAg levels with the ultrasensitive Lumipulse HBsAg iTACT assay and association with response and relapse - (11/24/25)   Up to 12 months' durability of functional cure with bepirovirsen plus Peg-IFN sequential therapy in B-Together responders: B-Sure study - (11/24/25)   The Dawn of a Cure for HBV, HBV Drug Pipeline - (11/24/25)   What Are the Major Barriers to Hepatitis B Elimination and How to Overcome Them, Expanded AASLD HBV Guidelines - (11/24/25)   Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator, Demonstrated Profound and Sustained Suppression of HBV DNA to < 10 IU/mL in All Treatment-Naïve (TN) or Currently-Not-Treated (CNT) Subjects with Chronic HBV Infection - (11/24/25)   Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved higher rate of sustained hepatitis B virus surface antigen loss on elebsiran plus peginterferon-alfa: Follow-up data from ENSURE study - (11/24/25)   Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small molecule PD-L1 inhibitor, in chronic hepatitis B (CHB) subjects - (11/24/25)   Imdusiran (AB-729) is safe and well tolerated after repeat dosing in chronic hepatitis B patients: An integrated safety analysis of Phase 1 and 2 imdusiran clinical trials - (11/24/25)   HBsAg declines observed with VRON-0200 alone are rapidly enhanced with the addition of combination antiviral therapies: results from a Phase 1b study for functional cure in chronically HBV-infected patients - (11/24/25)   Exposure to tenofovir alafenamide and tenofovir disoproxil fumarate and the risk of hepatocellular carcinoma - (11/24/25)   Elevations in Total Serum Bile Acids During Bulevirtide Treatment Are Asymptomatic and Not Associated With Adverse Events of Interest in Patients With Chronic Hepatitis Delta - (11/20/25)   Patient-Reported Burden and Health-Related Quality of Life Among Patients With Hepatitis Delta: Results From a Real-World Study in Europe - (11/20/25)   Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function - (11/20/25)   Integrated Virology Analysis of Bulevirtide Monotherapy in Chronic Hepatitis Delta: Pooled Data Through 96 Weeks of Treatment - (11/19/25)   Improvements in Patient-Reported General Health and Well-Being in Patients With Primary Biliary Cholangitis Treated With Seladelpar in the RESPONSE Trial - (11/19/25)   Your Guide to Living Well with Primary Biliary Cholangitis: Co-Creation of an Evidence-Based Resource for Symptom Management and Disease Understanding - (11/19/25)   Reduction in Itch-Associated Disability and Pruritus Distribution in Patients With Primary Biliary Cholangitis Treated With Seladelpar in the RESPONSE Trial - (11/19/25)   Real-World Experience of Seladelpar Among Patients With Primary Biliary Cholangitis Including Patients Who Switched From Obeticholic Acid - (11/19/25)   Clinical characteristics, disease status, and symptomatology of patients with primary biliary cholangitis in Europe and the United States of America: Analysis of a real-world dataset - (11/19/25)   Real-world assessment of current PBC treatment, key goals, and level of treatment satisfaction according to healthcare professionals across France, Italy, Germany, Spain, United Kingdom, and the United States - (11/19/25)   36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With Primary Biliary Cholangitis - (11/19/25)   Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Elevated Bilirubin at Baseline in the Phase 3 Placebo-Controlled RESPONSE Trial - (11/19/25)   Efficacy and Safety of Seladelpar vs. Elafibranor in Patients with Primary Biliary Cholangitis: A Matching-Adjusted Indirect Comparison (MAIC) - (11/19/25)   Sustained Efficacy and Safety of Seladelpar for up to 36 Months in Patients With Primary Biliary Cholangitis From the Placebo-Controlled RESPONSE Study to the Open-Label ASSURE Study - (11/19/25)   The Effectiveness of Bulevirtide Monotherapy is Similar in Chronic Hepatitis Delta Patients with & without Cirrhosis: Results from the Prospective Multicenter D-SHIELD Study - (11/17/25)   INVISIBLE FRONTLINES- COMBATING HEPATITIS C IN MEN WHO HAVE SEX WITH MEN AND TRANSGENDER COMMUNITIES - (11/17/25)   3 YEARS OF BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH HDV-RELATED COMPENSATED CIRRHOSIS: VIROLOGICAL OUTCOMES AND SAFETY DATA FROM THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (11/17/25)   SAFETY, EFFECTIVENESS AND CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS DELTA TREATED WITH BULEVIRTIDE MONOTHERAPY: A POOLED ANALYSIS ON 689 PATIENTS ENROLLED IN THE SAVE-D AND D-SHIELD STUDIES - (11/17/25)   EFFECT OF 48-WEEK BULEVIRTIDE THERAPY ON NON-INVASIVE MARKERS OF LIVER FIBROSIS IN PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B/D - (11/17/25)   HU6 Oral Investigational Therapy Reduces Liver Fat and Improves Adiposity Markers in Adults with MASH: Topline Results from a Phase 2 Randomized Placebo-Controlled Trial (M-ACCEL) - (11/16/25)   Impact of MASLD on the development of hepatocellular carcinoma after HCV cure in patients with chronic hepatitis C: A large-scale, multicenter cohort study - (11/16/25)   HIGH BURDEN OF LIVER FIBROSIS IN 4,809 PEOPLE WITH HIV MONOINFECTION UNDERGOING SCREENING FOR STEATOTIC LIVER DISEASE - (11/16/25)   A Randomized, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of Combination Treatment with Semaglutide, Cilofexor and Firsocostat in Patients With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (WAYFIND) - (11/16/25)   Role of Resmetirom in SLD: Beyond At-Risk MASH? - (11/16/25)   Two-year Time Course of Biomarker and Imaging Responses in Patients with Well-Compensated MASH Cirrhosis Treated With Resmetirom Two-year Time Course of Biomarker and Imaging Responses in Patients with Well-Compensated MASH Cirrhosis Treated With Resmetirom - (11/16/25)   MASLD in People Living with HIV: An Emerging Challenge - (11/16/25)   EVALUATING THE EARLY REAL-WORLD IMPACT OF RESMETIROM IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): A UNITED STATES COHORT STUDY USING ELECTRONIC MEDICAL RECORDS - (11/16/25)   Weight-dependent and independent effects of semaglutide in participants with MASH: Secondary analysis of the phase 3 ESSENCE trial - (11/16/25)   Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY) - (11/16/25)   Impact of Semaglutide on Cirrhosis and Complications in Patients with MASLD and Diabetes: A Retrospective Cohort Study - (11/13/25)   Seladelpar Leads to Sustained Reduction in Cholestatic Markers With Consistent Safety Profile in Patients With Primary Biliary Cholangitis up to 48 Months - (11/13/25)   Seladelpar Leads to Sustained, Clinically Meaningful Improvement in Pruritus: Results From the ASSURE Study up to 30 Months - (11/13/25)   Epidemiology and Outcomes of Primary Sclerosing Cholangitis in an Integrated Healthcare System - (11/13/25)   Symptom Burden and Treatment Patterns in Primary Biliary Cholangitis: A Systematic Review and Meta-analysis - (11/13/25)   Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis - (11/13/25)   Long-term data of elafibranor in primary sclerosing cholangitis: Interim safety and efficacy data from the ongoing open-label extension of the ELMWOOD phase II trial - (11/13/25)   FROM DISCOVERY TO CURE - WHERE ARE WE NOW? MORTALITY TRENDS IN CHRONIC HEPATITIS C: AN ANALYSIS OF THE CDC WONDER DATABASE (1999-2024) - (11/13/25)   Is SVR4 Testing an Acceptable Alternative Measure of HCV Cure in Re-Treated Patients Following DAA Failure? An SVR4/12 Concordance Evaluation From the POLARIS Clinical Trials - (11/13/25)   TALES FROM OPPOSITE CORNERS OF THE WORLD COST-EFFECTIVENESS OF EMERGENCY DEPARTMENT BLOOD-BORNE VIRUS OPT-OUT TESTING TO ADVANCE ELIMINATION TARGETS FOR VIRAL HEPATITIS AND HIV TRANSMISSION IN AUSTRALIA AND GERMANY - (11/13/25)   Real-World Implications of the New AASLD/IDSA HCV "Test and Treat" Algorithm: Focus on Cardiovascular Comedications in Hepatitis C Virus (HCV) Patients Receiving Direct-Acting Antivirals (DAAs - (11/13/25)   Barriers and Proposed Interventions to Improve Hepatocellular Carcinoma Surveillance Adherence in Patients with Hepatitis C Virus Post-Sustained Virologic Response: A Qualitative Survey Assessment of Hepatology Experts - (11/13/25)   Rural-Urban Trends in Liver-Related Mortality Post-Pandemic Differ by Etiology and Age - (11/13/25)   High SVR Rates Achieved with Simplified Monitoring in Japanese Patients with HCV Infection Treated with Sofosbuvir/Velpatasvir: A Prospective multicenter Study - (11/13/25)   REAL-WORLD OUTCOMES OF SOFOSBUVIR/VELPATASVIR IN A VARIETY OF HEPATITIS C PATIENT POPULATIONS: A RETROSPECTIVE COHORT STUDY - (11/13/25)   NATIONAL POPULATION-BASED HEPATITIS C SCREENING AND ELIMINATION PROGRAMME IN LITHUANIA: WHAT RESULTS HAVE WE ACHIEVED? - (11/13/25)   Global Progress Towards Hepatitis C Elimination: Monitoring Achievements of WHO Goals & Targets for Hepatitis C Prevention & Care - (11/13/25)   Real-World Trends in Hepatitis C Virus (HCV) Antibody Screening and Positivity Rates, 2020-2024: Analysis of > 35 Million US Adult Patients - (11/13/25)   Efficacy and Safety of Tobevibart (VIR-3434) Alone or in Combination With Elebsiran (VIR-2218) in Participants With Chronic Hepatitis Delta Virus Infection: Week 48 Endpoint Analysis From the Phase 2 SOLSTICE Trial - (11/13/25)   Safety and Pharmacokinetics of BJT-628, an Orally Available Liver-Targeted HBV Transcript Inhibitor for the Treatment of Chronic Hepatitis B in Healthy Volunteers - (11/12/25)   Brelovitug (BJT-778) Binds a Conformational Epitope Highly Conserved Across HBV Genotypes - (11/12/25)   Immune Complexes of BJT-778 Enhance Cross-Presentation of HBsAg and Activation of CD8+ T Cells - (11/12/25)   Effect of Direct Acting Antiviral Treatment on Hepatic Steatosis in Patients with Chronic Hepatitis C - (11/12/25)   Persistent Low Viremic Relapse vs High Viremic Relapse After the End of Treatment With Bulevirtide With or Without Pegylated Interferon in Patients With Chronic Hepatitis Delta Virus - (11/12/25)   Real-World Persistency of Bulevirtide Therapy in Chronic Hepatitis D Patients in Germany: A Retrospective Observational Analysis - (11/12/25)   Disease Progression Among Commercially Insured Patients Infected With Hepatitis Delta Virus in the United States - (11/12/25)   ECLIPSE: A Pivotal Program Evaluating Once-Monthly Combination Therapy With Tobevibart and Elebsiran for Chronic HDV Infection - Rationale, Study Design, and Objectives - (11/12/25)   Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response in Patients with Chronic Hepatitis D: On Treatment Week 48 Phase 2 Study Results - (11/12/25)   INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA AFTER SUSTAINED VIROLOGIC RESPONSE CHANGE OVER TIME IN PATIENTS WITH HEPATITIS C VIRUS TREATED WITH DIRECT-ACTING ANTIVIRAL - (11/10/25)   THE IMPACT OF VIRAL CLEARANCE BY DIRECT-ACTING ANTIVIRAL ON PROGNOSIS AND LIVER-RELATED EVENTS IN HEPATITIS C VIRUS-RELATED DECOMPENSATED CIRRHOSIS - (11/10/25)   Prediction of liver-related events after sustained virological response in patients with decompensated HCV cirrhosis - (11/10/25)   THE MAJORITY OF PATIENTS WITH HEPATITIS C NOT ACHIEVING SVR CAN BE SUCCESSFULLY RETREATED WITH FIRST-LINE REGIMENS: RESULTS FROM A MULTIDISCIPLINARY TEAM APPROACH TO GUIDE TREATMENT DECISIONS - (11/10/25)   Cumulative Review of Sofosbuvir/Velpatasvir exposure in pregnant women with Hepatitis C from a Pharmacovigilance Safety Database - (11/10/25)   Predictors of Reinfection among Participants in a Hepatitis C Treatment Trial in Rural Appalachia - (11/10/25)   LINKING PERSONS WITH A HISTORY OF EXPERIENCING HOMELESSNESS TO HCV CARE BY ESTABLISHING DATA EXCHANGE BETWEEN A PUBLIC HEALTH HEPATITIS C VIRUS REGISTRY AND A HOMELESS SERVICES AGENCY - LOS ANGELES COUNTY, JANUARY-MAY, 2025 - (11/10/25)   Global treatment rate and impact of direct-acting antiviral on clinical outcomes in HCV-related hepatocellular carcinoma: a systematic review and meta-analysis - (11/10/25)   SOFOSBUVIR-BASED REGIMEN ACHIEVED HIGH VIROLOGICAL RESPONSE IN NON-GENOTYPED HCV PATIENTS FROM A GENOTYPE 3 HIGH-PREVALENCE REGION OF SOUTHWEST CHINA: A RETROSPECTIVE COHORT STUDY (SAIN-C) - (11/10/25)   SOFOSBUVIR-BASED REGIMEN ACHIEVED HIGH VIROLOGICAL RESPONSE IN NON-GENOTYPED HCV PATIENTS FROM A GENOTYPE 3 HIGH-PREVALENCE REGION OF SOUTHWEST CHINA: A RETROSPECTIVE COHORT STUDY (SAIN-C) - (11/10/25)   Hepatitis C Care Cascade Using Direct Acting Antiviral Medications in Rural New York State from 2013-2023; A Retrospective Study - (11/09/25)   FROM DISCOVERY TO CURE - WHERE ARE WE NOW? MORTALITY TRENDS IN CHRONIC HEPATITIS C: AN ANALYSIS OF THE CDC WONDER DATABASE (1999-2024) - (11/09/25)   Gender and Socioeconomic-Based Disparities in Hepatitis C Treatment and Cure Rates in an Emergency Department-Based Screening and Treatment Program - (11/09/25)   RE-ENGAGEMENT TO RESCUE THERAPY WITH SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR IN HEPATITIS C AFTER DIRECT-ACTING ANTIVIRAL FAILURE - (11/09/25)   Safety and efficacy of 8-weeks Glecaprevir/Pibrentasvir in persons with acute hepatitis C in Germany and Austria - (11/09/25)   Avoiding the Impact of Inaction: How to Maximize Progress to HCV Elimination in the United States - (11/09/25)   Timing is Everything: Economic Implications of Immediate Versus Delayed Hepatitis C Care - (11/09/25)   Sofosbuvir Based Regimens are Effective for Hepatitis C Treatment for End-Stage Renal Disease Patients in Real-Life Setting - (11/09/25)   TALES FROM OPPOSITE CORNERS OF THE WORLD COST-EFFECTIVENESS OF EMERGENCY DEPARTMENT BLOOD-BORNE VIRUS OPT-OUT TESTING TO ADVANCE ELIMINATION TARGETS FOR VIRAL HEPATITIS AND HIV TRANSMISSION IN AUSTRALIA AND GERMANY - (11/09/25)   Is SVR4 Testing an Acceptable Alternative Measure of HCV Cure in Re-Treated Patients Following DAA Failure? An SVR4/12 Concordance Evaluation From the POLARIS Clinical Trials - (11/09/25)